Diamonds in the Rough
Cross-referencing fundamental value against technical exhaustion to isolate beaten-down XBI constituents that screen cheap and oversold. The bottom-right quadrant — high earnings yield, low RSI — is the prime hunting ground, especially where money flow (MFI) shows quiet accumulation despite the falling price.
Educational screen, not investment advice. “Diamond” classification is a mechanical valuation-vs-RSI split around the cohort median earnings yield and an RSI of 50.
Alpha Quadrant — Valuation × Technical Exhaustion
X = earnings yield (cheaper right) · Y = RSI 14 (more oversold lower) · bubble = market cap · color = money flow.
Diamond Candidates
Ranked by a composite of earnings yield, ROIC, oversold RSI, recent weakness, and improving money flow.
| # | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | BCRX | BioCryst Pharmaceuticals Inc | 80.7 | 12.43% | 1.57 | 32 | -22.29% | 35 | distress |
| 2 | IRWD | Ironwood Pharmaceuticals, Inc. - Class A | 72.8 | 10.05% | 2.79 | 50 | -5.44% | 49 | distress |
| 3 | PTCT | PTC Therapeutics, Inc. | 70.4 | 17.15% | 0.64 | 35 | -9.11% | 20 | safe |
| 4 | ADMA | ADMA Biologics, Inc. | 58.2 | 9.00% | 0.41 | 43 | -7.21% | 30 | safe |
| 5 | AMGN | Amgen Inc | 57.7 | 4.27% | 0.72 | 34 | -9.15% | 32 | grey |
| 6 | UTHR | United Therapeutics Corp | 55.9 | 7.65% | 0.31 | 46 | -2.51% | 57 | safe |
| 7 | NVAX | Novavax Inc | 49.8 | 27.28% | 0.75 | 57 | +19.73% | 59 | distress |
| 8 | RIGL | Rigel Pharmaceuticals Inc. (New) | 48.2 | 14.57% | 0.89 | 51 | +6.66% | 38 | safe |
| 9 | INCY | Incyte Genomics Inc | 47.0 | 7.79% | 0.34 | 46 | -0.03% | 34 | safe |
| 10 | MDXG | MiMedx Group, Inc | 46.8 | 7.22% | 0.20 | 61 | +8.41% | 65 | safe |
| 11 | EBS | Emergent Biosolutions, Inc. | 45.9 | 7.97% | 0.09 | 57 | +41.15% | 76 | grey |
| 12 | ALKS | Alkermes Inc. plc | 45.3 | 2.92% | 0.29 | 37 | -11.29% | 34 | safe |
| 13 | EXEL | Exelixis Inc | 43.4 | 6.40% | 0.77 | 51 | +11.22% | 45 | safe |
| 14 | VCYT | Veracyte, Inc. | 40.0 | 1.93% | 0.13 | 39 | -8.89% | 54 | safe |
| 15 | ARWR | Arrowhead Research Corporation | 38.5 | 2.40% | 0.25 | 39 | -7.91% | 35 | safe |
Short-Squeeze Watch
Constituents with the highest composite squeeze score — heavy short interest meeting price support.
| # | |||||||
|---|---|---|---|---|---|---|---|
| 1 | TYRA | Tyra Biosciences, Inc. Common Stock | 94.4 | 28.24% | 27.14 | -1.03% | critical |
| 2 | IBRX | ImmunityBio, Inc. Common Stock | 92.2 | 31.81% | 14.77 | +7.31% | critical |
| 3 | VOR | Vor Biopharma Inc. Common Stock | 90.0 | 57.99% | 10.37 | +4.86% | critical |
| 4 | BBOT | BridgeBio Oncology Therapeutics, Inc. Common Stock | 89.5 | 24.97% | 20.77 | -46.73% | critical |
| 5 | ZBIO | Zenas BioPharma, Inc. Common Stock | 86.5 | 40.15% | 14.18 | +5.00% | critical |
| 6 | SMMT | Summit Therapeutics Inc. Common Stock | 86.2 | 30.05% | 6.62 | +21.50% | critical |
| 7 | SPRY | ARS Pharmaceuticals, Inc. Common Stock | 85.9 | 47.38% | 14.14 | -25.99% | critical |
| 8 | KOD | Kodiak Sciences Inc Common Stock | 85.7 | 34.54% | 18.45 | -24.37% | critical |
| 9 | ALLO | Allogene Therapeutics, Inc. Common Stock | 84.5 | 34.78% | 12.15 | -16.43% | critical |
| 10 | ANAB | AnaptysBio, Inc. Common Stock | 83.8 | 31.00% | 15.59 | -5.19% | critical |
| 11 | RXRX | Recursion Pharmaceuticals, Inc. Class A Common Stock | 83.4 | 41.27% | 10.60 | +3.02% | critical |
| 12 | INBX | Inhibrx Biosciences, Inc. Common Stock | 82.9 | 35.49% | 10.39 | +10.53% | critical |
Market cap, valuation, and short-interest metrics are joined to the latest XBI holdings snapshot; each ticker links to its full quote and analysis page.